| DB ID | MyCo_3197 |
| Title | β-D-Glucan and Candida albicans germ tube antibody in ICU patients with invasive candidiasis |
| Year | 2015 |
| PMID | 26134359 |
| Fungal Diseases involved | Invasive candidiasis |
| Associated Medical Condition | None |
| Genus | Candida |
| Species | albicans |
| Organism | Candida albicans |
| Ethical Statement | The study protocol was approved by the institutional review board, Hospital Universitario de Valme, Universidad de Sevilla, Sevilla, Spain and informed consent was obtained from the patients or their legal representatives. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Spain |
| Cohort | Between 1 January 2011 and 30 December 2012, unse-lected, non-neutropenic critically ill patients admitted for at least 7 days to a medical-surgical ICU in Sevilla, Spain, were included in a prospective, cohort, and observational study. Of 148 eligible patients, 41 (27.7 %) were excluded. |
| Cohort No. | 107 |
| Age Group | None |
| P Value | p=0.012 |
| Sensitivity | 80% |
| Specificity | 44.60% |
| Positive Predictive Value | 93.20% |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | ELISA |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | Immunofluorescence test Kit (VircellÒ kit assay, Granada, Spain) |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
